FBT:ARCA-First Trust Amex Biotech Index Fund

ETF | Health | NYSE Arca

Last Closing Price

USD 144.28

Change

0.00 (0.00)%

Market Cap

USD 2.73B

Volume

0.24M

Average Target Price

N/A
Average Analyst Rating

N/A

STA Verdict

Verdict

About

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets (including investment borrowings) in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. It is non-diversified.

Inception Date: 19/06/2006

Primary Benchmark: NYSE Arca Biotechnology TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.55%

Management Expense Ratio: 0.56 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-19 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
XLV SPDR Select Sector Fund - Heal.. 0.13 %

N/A

USD 18.86B
VHT Vanguard Health Care 0.10 %

N/A

USD 8.82B
XBI SPDR Series Trust S&P Biotech 0.35 %

N/A

USD 4.13B
IHI iShares U.S. Medical Devices 0.43 %

N/A

USD 2.83B
IYH iShares U.S. Healthcare 0.43 %

N/A

USD 2.46B
FXH First Trust Health Care AlphaD.. 0.62 %

N/A

USD 2.03B
IXJ iShares Global Healthcare 0.47 %

N/A

USD 2.03B
FHLC Fidelity MSCI Health Care Inde.. 0.08 %

N/A

USD 1.53B
IHF iShares U.S. Health Care Provi.. 0.43 %

N/A

USD 0.88B
HQH Tekla Healthcare Investors 0.00 %

N/A

USD 0.87B

ETFs Containing FBT

FVC First Trust Dorsey Wright.. 19.35 % 0.30 %

N/A

USD 0.52B
FV First Trust Dorsey Wright.. 19.27 % 0.30 %

N/A

USD 2.26B
DALI First Trust DorseyWright .. 12.66 % 0.00 %

N/A

USD 0.05B

Market Performance

  Market Performance vs.
Industry/Classification (Health)
Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.17% 86% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.17% 86% B 87% B+
Trailing 12 Months  
Capital Gain 8.42% 89% B+ 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.42% 82% B- 87% B+
Trailing 5 Years  
Capital Gain 89.39% 95% A 92% A-
Dividend Return 0.24% 5% F 2% F
Total Return 89.64% 86% B 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 15.96% 89% B+ 88% B+
Dividend Return 16.00% 89% B+ 86% B
Total Return 0.05% 4% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 24.90% 11% F 25% F
Risk Adjusted Return 64.28% 50% F 66% D
Market Capitalization 0.85B 86% B 70% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.